Biosilu Healthcare AG (1YA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Biosilu Healthcare AG (1YA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011872
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Biosilu Healthcare AG (Biosilu Healthcare), formerly Amp Biosimilars AG is a life science company that develops and commercializes biopharmaceuticals. The company’s product pipeline comprises biosimilar development projects on immune disorders and cancer. It offers products in therapeutic areas of infectious diseases, fertility, tumor indications and other rare diseases. Biosilu Healthcare also provides advises for Asian biopharmaceutical companies and investors in outreach to Western markets, partners and investment opportunities. The company develops products with a clinical-proof-of-concept in areas of high medical needs in Asia. It partners with western biopharmaceutical companies. The company operates in Germany and China. Biosilu Healthcare is headquartered in Frankfurt, Germany.

Biosilu Healthcare AG (1YA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Biosilu Healthcare AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Biosilu Healthcare AG, Medical Devices Deals, 2011 to YTD 2017 9
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
amp biosimilars Enters into Licensing Agreement for ABY-021 Biosimilar 11
amp biosimilars Enters into Licensing Agreement for Biosimilar 12
Equity Offering 13
Biosilu Healthcare Raises USD0.5 Million in Private Placement of Shares 13
amp biosimilars Raises USD28.67 Million in IPO 14
Biosilu Healthcare AG – Key Competitors 15
Biosilu Healthcare AG – Key Employees 16
Biosilu Healthcare AG – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Jun 28, 2016: amp biosimilars announces Klaus K. Wilgenbus as new CEO 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Key Facts 2
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Biosilu Healthcare AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Biosilu Healthcare AG, Deals By Therapy Area, 2011 to YTD 2017 8
Biosilu Healthcare AG, Medical Devices Deals, 2011 to YTD 2017 9
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
amp biosimilars Enters into Licensing Agreement for ABY-021 Biosimilar 11
amp biosimilars Enters into Licensing Agreement for Biosimilar 12
Biosilu Healthcare Raises USD0.5 Million in Private Placement of Shares 13
amp biosimilars Raises USD28.67 Million in IPO 14
Biosilu Healthcare AG, Key Competitors 15
Biosilu Healthcare AG, Key Employees 16

★海外企業調査レポート[Biosilu Healthcare AG (1YA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • amcure GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Amcure GmbH (Amcure) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of cancer. The company develops peptide-based compounds for the treatment of metastatic forms of cancer. Its lead candidate, AMC303 is used for the treatment of metastatic epithelia …
  • Arriva plc:企業の戦略・SWOT・財務情報
    Arriva plc - Strategy, SWOT and Corporate Finance Report Summary Arriva plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Swietelsky Baugesellschaft mbH:企業の戦略的SWOT分析
    Swietelsky Baugesellschaft mbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Passenger Rail Agency of South Africa:企業の戦略的SWOT分析
    Passenger Rail Agency of South Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Vector Ltd (VCT):企業の財務・戦略的SWOT分析
    Vector Ltd (VCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • OPG Power Ventures Plc (OPG):企業の財務・戦略的SWOT分析
    OPG Power Ventures Plc (OPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Universal Power Group Inc (UPGI):企業の財務・戦略的SWOT分析
    Summary Universal Power Group Inc (UPG) a subsidiary of UPGI Holdings Inc, is a provider of electric mobility products. The company through its subsidiaries supplies and distributes batteries and related power accessories. It offers sealed lead-acid batteries, ap series batteries, hc series batterie …
  • CanBas Co Ltd (4575)-製薬・医療分野:企業M&A・提携分析
    Summary CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that provides drugs. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It product under development is CBP501, a modified synthetic peptide enhancing the efficacy of …
  • Sherwin-Williams Co (SHW):企業の財務・戦略的SWOT分析
    Sherwin-Williams Co (SHW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bank Hapoalim BM:企業の戦略・SWOT・財務情報
    Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report Summary Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Danone SA:企業の戦略・SWOT・財務情報
    Danone SA - Strategy, SWOT and Corporate Finance Report Summary Danone SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Otter Tail Corporation:発電所・企業SWOT分析
    Otter Tail Corporation – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employ …
  • BioLamina AB-製薬・医療分野:企業M&A・提携分析
    Summary BioLamina AB (BioLamina) is a biotechnology company that focuses on the development, manufacture and distribution of cell culture reagents intended for culturing primary cells. The company offers a wide portfolio of chemically defined and xeno-free laminin proteins. Its product portfolio inc …
  • Nisshinbo Holdings Inc (3105):企業の財務・戦略的SWOT分析
    Nisshinbo Holdings Inc (3105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Southwestern Electric Power Co:企業の戦略的SWOT分析
    Southwestern Electric Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • MISC Berhad (MISC):石油・ガス:M&Aディール及び事業提携情報
    Summary MISC Bhd (MISC), a subsidiary of Petroliam Nasional Berhad (Petronas), is an international energy shipping and maritime conglomerate. The company is a fully integrated maritime, offshore floating solution, heavy engineering and logistics service provider. Its principal business activities in …
  • Hogan Lovells International LLP:企業の戦略的SWOT分析
    Hogan Lovells International LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Jiuzhitang Co Ltd (000989):製薬・医療:M&Aディール及び事業提携情報
    Summary Jiuzhitang Co Ltd (Jiuzhitang), formerly Labor Jiuzhitang Pharmacy, is a Chinese medicine manufacturing company. The company offers products such as shuxuetong injection, lujiao granule, liuwei dihuang wan pills, zuguang power, siqikang injection, luo hua zi zhu tablets, compound jiangzhi ta …
  • Mahindra Holidays & Resorts India Limited:企業の戦略・SWOT・財務分析
    Mahindra Holidays & Resorts India Limited - Strategy, SWOT and Corporate Finance Report Summary Mahindra Holidays & Resorts India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Damac Real Estate Development Ltd:企業の戦略・SWOT・財務分析
    Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆